Artificial intelligence (AI) biotech company Deep Bio on Tuesday announced a collaboration with Visiopharm to integrate its prostate cancer diagnosis support software into Visiopharm’s digital pathology platform.
DeepDx Prostate is deep learning-based software used in prostate core needle biopsy tissue image analysis to identify cancerous areas and grade their severity by providing a Gleason score.
The collaboration brings the software to Visiopharm’s European diagnostic customers, allowing pathologists to obtain an analysis of whole-slide images of H&E-stained biopsy tissue specimens, Deep Bio said.
The first phase involving the integration of DeepDx into Visiopharm's digital pathology platform has been completed. Deep Bio and Visiopharm said that a second phase will aim to improve interoperability between the platform and AI solutions.
Visiopharm and Deep Bio will also scale the solution up as interest grows and add AI-based cancer pathology solutions for prostate and breast cancer, Deep Bio said.